ACI 24
Alternative Names: ACI-24; ACI-24.060; Anti-Abeta vaccine - AC immune; Pal1-15 acetate saltLatest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator AC Immune
- Developer AC Immune; University of California, San Diego
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
- Phase I/II Down syndrome
Most Recent Events
- 09 Dec 2024 Adverse event data from the phase I/II trial in Alzheimer's disease released by AC Immune
- 28 Jul 2024 Immunogenicity data from a preclinical study in Alzheimer’s disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 28 May 2024 No recent reports of development identified for phase-I development in Down syndrome in USA (SC, Injection)